Downregulation of MMP-9 activity in circulation is essential for HF patients since high levels of this enzyme are related to heart fibrosis, microvascular complications, peripheral arterial dysfunction, acute myocardial infarction, and unfavorable prognosis [42,43,44,45,46]. This evidence concerns the gene MMP9 and myocardial infarction.